Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 1, 2007, Pages 1-7

  Xu, N ^a   Shen, P ^a   Zhang, X C ^a   Yu, L F ^a   Bao, H Y ^a   Shi, G M ^a   Huang, S ^a   Chen, J ^a   Mou, H B ^a   Fang, W J ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Carboplatin; Chemotherapy; Fixed infusion; Gemcitabine; Non small cell lung cancer

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CREATININE; GEMCITABINE; HEMOPOIETIC GROWTH FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LARGE CELL CARCINOMA; LEUKOPENIA; LIVER DYSFUNCTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; ENDPOINT DETERMINATION; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 33751278973     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0237-2     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J et al (2005) Global Cancer Statistics, 2002. CA Cancer J Clin 55:74-108
2. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in Non-Small Cell Lung Cancer (1995) A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909
3. Le Chevalier T, Brisgand D, Douillard JY et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367
4. Wozniak AJ, Crowley JJ, Balcerzak SP et al (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16:2459-2465
5. Bonomi P, Kim K, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-631
6. Sandler AB, Nemunaitis J, Denham C et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 18:122-130
7. Crino L, Scagliotti GV, Ricci S et al (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17:3522-3530
8. Scagliotti GV, De Marinis F, Rinaldi M et al (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer Italian Lung Cancer Project. J Clin Oncol 20:4285-4291
9. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer Eastern Cooperative Oncology Group. N Engl J Med 346:92-98
10. Kelly K, Crowley J, Bunn PA Jr et al (2001) Randomized phase III trial of paclitaxel pluscarboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19:3210-3218
11. Smit EF, van Meerbeeck JP, Lianes P et al (2003) Three-arm randomized study of two cisplatinbased regimens and paclitaxel plus gemcitabine in advanced non-smallcell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 21:3909-3917
12. Le Chevalier T, Scagliotti G, Natale R et al (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69-80
13. Gandhi V, Plunkett W (1990) Modulatory activity of 2′,2′- difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50:3675-3680
14. Plunkett W, Huang P, Xu Y et al (1995) Gemcitabine: metabolism, mechanisms of action, and self potentiation. Semin Oncol 22:3-10
15. Grunewald R, Kantarjian H, Keating MJ et al (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′- difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823-6826
16. Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498
17. Grunewald R, Abbruzzese JL, Tarasoff P et al (1991) Saturation of 2′,2′-difluorodeoxycytidine 5′ triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258-262
18. Grunewald R, Kantarjian H, Du M et al (1992) Gemcitabine (2′,2′-difluorodeoxycytidine) in leukemia: a phase I clinical, plasma and cellular pharmacology study. J Clin Oncol 10:406-413
19. Tempero M, Plunkett W, Ruiz van Haperen V et al (2003) Randomized phase II comparison of dose intense Gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408
20. Schmid P, Akrivakis K, Flath B et al (1999) Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10:625-631
21. Touroutoglou N, Gravel D, Raber MN et al (1998) Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9:1003-1008
22. Cortesi E, Barduagni M, Antimi M et al (2003) Prolonged gemcitabine infusion in non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98:337-343
23. Van Echo DA, Egorin MJ, Aisner J (1989) The pharmacology of carboplatin. Semin Oncol 16:1-6
24. Carmichael J, Allerheiligen S, Walling J (1996) A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol 23:55-59
25. Ng EW, Sandler AB, Robinson L et al (1999) A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a Hosier Oncology Group study. Am J Clin Oncol 22:550-553
26. Carrato A, Garcia-Gomez J, Alberola V et al (1999) Carboplatin (carbo) in combination with gemcitabine (gem) in advanced non-small cell lung cancer (NSCLC): comparison of two consecutive phase II trials using different schedules. Proc Am Soc Clin Oncol 18:498
27. Parente B, Barrosa A, Conde S et al (2001) A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three versus a four-week schedule. Semin Oncol 28:10-14
28. Jovtis S, Brocato N, Balbiani L et al (1999) First-line therapy with gemcitabine (GEMTRO) (G) and carboplatin (C) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II study. Proc Am Soc Clin Oncol 18:510
29. Sederholm C (2002) Gemcitabine (G) compared with gemcitabine plus carboplatin in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 21:1162
30. Gross C, Holiday D, Hampton J et al (1999) A combination therapy of gemcitabine (GEM) and carboplatin (CBDCA) in advanced stage non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 18:1955
31. Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756
32. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
33. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
34. Zatloukal P, Petruzelka L, Zemanova M et al (2003) Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 41:321-331
35. Rudd RM, Gower NH,Spiro SG et al (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIb or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23:142-153
36. Soo RA, Lim HL, Wang LZ et al (2003) Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study. Cancer Chemother Pharmacol 52:153-158
37. Domine M, Estevez L, Leon A et al (2002) A phase II trial of a two hour infusion of gemcitabine with carboplatin for advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:225b
38. De Castro J, Lorenzo A, Morales S et al (2005) Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma. Cancer Chemother Pharmacol 55:197-202